-
Jones Trading Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI) following earnings
-
TriSalus Life Sciences (TLSI) Misses Q4 EPS by 21c
-
TriSalus reports Q4 revenue of $13.2 million, up 60% year-over-year
-
Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)
-
TriSalus Life Sciences (TLSI) Misses Q3 EPS by 96c
-
TriSalus Life Sciences (TLSI) files $150M mixed shelf
-
Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)
-
TriSalus publishes thyroid embolization study results
-
TriSalus completes exchange offer for preferred stock
-
TriSalus Life Sciences (TLSI) commences exchange offer
-
Cantor Fitzgerald Reiterates Overweight Rating on TriSalus Life Sciences, Inc. (TLSI)
-
Cantor Fitzgerald Reiterates Overweight Rating on TriSalus Life Sciences, Inc. (TLSI)
-
TriSalus Life Sciences (TLSI) Announces CFO Change
-
Cantor Fitzgerald Reiterates Overweight Rating on TriSalus Life Sciences, Inc. (TLSI)
-
Northland Reiterates Outperform Rating on TriSalus Life Sciences, Inc. (TLSI)
-
TriSalus Life Sciences (TLSI) Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Lake Street Capital Markets Starts TriSalus Life Sciences, Inc. (TLSI) at Buy
-
TriSalus Life Sciences (TLSI) Appoints William J. Valle and Gary B. Gordon to its Board
-
TriSalus Life Sciences (TLSI) Reports Prelim Q4 Results
-
TriSalus Life Sciences (TLSI) Announces Leadership Changes
-
TriSalus Life Sciences, Inc. (TLSI) PT Lowered to $11 at Canaccord Genuity
-
Roth/MKM Starts TriSalus Life Sciences, Inc. (TLSI) at Buy
-
Northland Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform
-
TriSalus Life Sciences (TLSI) Appoints Riad Salem to its Board
-
TriSalus Life Sciences (TLSI) Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With P
-
Oppenheimer Starts TriSalus Life Sciences, Inc. (TLSI) at Outperform, PT $10
-
Jones Trading Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)
-
Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)

